Accès gratuit
Med Sci (Paris)
Volume 18, Numéro 10, Octobre 2002
Page(s) 975 - 981
Section M/S Revues : Articles de Synthèse
Publié en ligne 15 octobre 2002
  1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65 : 635–92.
  2. Champoux JJ. Mechanistic aspects of type-I topoisomerases. In : Wang JC, Cozarelli NR, eds. DNA topology and its biological effects. Cold Spring Harbor, NY : Cold Spring Harbor Laboratory Press, 1990 : 217–42.
  3. Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomerase I. Science 1998; 279 : 1534–41.
  4. Svejstrup JQ, Christiansen K, Gromova II, et al. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J Mol Biol 1991; 222 : 669–78.
  5. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49 : 5077–82.
  6. Pommier Y, Pourquier P, Urasaki Y, et al. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999; 2 : 307–18.
  7. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000; 7 : 39–58.
  8. Holm C, Covey JM, Kerrigan D, et al. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49 : 6365–8.
  9. Shykind BM, Kim J, Stewart L, et al. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev 1997; 11 : 397–407.
  10. Haluska P Jr, Saleem A, Rasheed Z, et al. Interaction between human topoisomerase I and a novel RING finger/arginineserine protein. Nucleic Acids Res 1999; 27 : 2538–44.
  11. Bhart AK, Olson MO, Kufe DW, et al. Identification of a nucleolin binding site in human topoisomerase I. J Biol Chem 1996; 271 : 1993–7.
  12. Rossi F, Labourier E, Forne T, et al. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996; 381 : 80–2.
  13. Straub T, Grue P, Uhse A, et al. The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I activity by a direct interaction. J Biol Chem 1998; 273 : 26261–4.
  14. Shuman S. Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. J Biol Chem 1994; 269 : 32678–84.
  15. Krogh BO, Shuman S. Catalytic mechanism of DNA topoisomerase IB. Mol Cell 2000; 5 : 1035–41.
  16. Cheng C, Kussie P, Pavletich N, et al. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases. Cell 1998; 92 : 841–50.
  17. Bullock P, Champoux JJ, Botchan, M. Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination. Science 1985; 230 : 954–8.
  18. Wang HP, Rogler CE. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 1991; 65 : 2381–92.
  19. Zhu J, Schiestl RH. Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol 1996; 16 : 1805–12.
  20. Anderson RD, Berger NA. International commission for protection against environmental mutagens and carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994; 309 : 109–42.
  21. Lanza A, Tornaletti S, Rodolfo C, et al. Human DNA topoisomerase Imediated cleavages stimulated by ultraviolet light-induced DNA damage. J Biol Chem 1996; 271 : 6978–86.
  22. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001; 80 : 189–216.
  23. Pourquier P, Kohlhagen G, Ueng LM, et al. Topoisomerase I and II activity assays. In : Brown R, Böger-Brown U, eds. Cytotoxic drug resistance mechanisms. Totowa : Humana Press Inc, 1999 : 95–110.
  24. Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279 : 1504–13.
  25. Pourquier P, Takebayashi Y, Urasaki Y, et al. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci USA 2000; 97 : 1885–90.
  26. Subramanian D, Kraut E, Staubus A, et al. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995; 55 : 2097–103.
  27. Mao Y, Okada S, Chang LS, et al. p53 dependence of topoisomerase I recruitment in vivo. Cancer Res 2000; 60 : 4538–43.
  28. Gobert C, Bracco L, Rossi F, et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996; 35 : 5778–86.
  29. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266 : 1376–80.
  30. Nitiss JL, Nitiss KC, Rose A, et al. Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage. J Biol Chem 2001; 276 : 26708–14.
  31. Pourquier P, Kohlhagen G, Urasaki Y, et al. Induction of topoisomerase I cleavage complexes by staurosporine in apoptotic leukemia cells: could topoisomerase I act as an apoptotic endonuclease? Proc Am Assoc Cancer Res 2001; 42 : 303.
  32. Bonven BJ, Gocke E, Westergaard O. A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell 1985; 41 : 541–51.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.